PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial

Summary

This clinical trial examines positron emission tomography (PET)/computed tomography (CT) in evaluating cardiac radiation damage in patients with lung or esophageal cancer. As part of the treatment for lung or esophageal cancer, patients will undergo radiation therapy. Sometimes, during this treatment, the heart is also subjected to some radiation which could affect its function, either increasing or decreasing the function. It is not known the consequences of this change nor is it known if doctors can detect the changes associated with the radiation. Sarcoidosis FDG positron emission tomography (PET)-computed tomography (CT) scans are a common way to image cardiac inflammation and myocardial viability. This study may help doctors image the heart before, during and after radiotherapy to monitor any changes.

Eligibility

Inclusion Criteria:

* Provide signed and dated informed consent form
* Willing to comply with all study procedures and be available for the duration of the study
* Male or female, aged \>= 18
* Life expectancy \>= 3 months as assessed by Radiation Oncologist
* Mean heart dose estimated by Radiation Oncologist to be \>= 5 Gy (physics dose or biologically equivalent dose)
* Pathologically proven (either histologic or cytologic) proven lung cancer or esophageal cancer
* Planned radiation treatment course for management of lung or esophageal cancer \* Both standard and hypofractionation schedules are permitted

Exclusion Criteria:

* Contraindication for FDG PET-CT scans as assessed by the radiation oncologist or nuclear medicine radiologist
* Palliative radiation doses defined as 20 Gy in 5 fractions

Conditions5

Locations1 site

Browse More Trials